Home > News > American Pharmaceutical Partners Reports Tolerability of High Dose
June 8th, 2004
American Pharmaceutical Partners Reports Tolerability of High Dose
Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. today reported results of a Phase I dose-escalation study of ABRAXANETM (albumin nanoparticle paclitaxel) that indicated this investigational drug is well-tolerated at high doses in a weekly dosing schedule for non-hematologic malignancies such as lung, ovarian and metastatic breast cancer and patients who have had prior chemotherapies.
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015
Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015
New nanodevice defeats drug resistance: Tiny particles embedded in gel can turn off drug-resistance genes, then release cancer drugs March 2nd, 2015